Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

04 Dec 2023 According to Trial design presented in the International Journal of Gynecological Cancer, The Last-Patient-In is expected to be enrolled in September 2024, with presentation of the primary endpoint in 2028
04 Dec 2023 Trial design presented in the International Journal of Gynecological Cancer.
04 Sep 2022 Status changed to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com